Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against leishmania infections: Preparation, characterization and macrophage uptake

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorPires, Vinícius Couto-
Autor(es): dc.creatorMagalhães, Carla Pires-
Autor(es): dc.creatorFerrante, Marcos-
Autor(es): dc.creatorRebouças, Juliana de Souza-
Autor(es): dc.creatorNguewa, Paul-
Autor(es): dc.creatorSeverino, Patrícia-
Autor(es): dc.creatorBarral, Aldina-
Autor(es): dc.creatorVeras, Patrícia Sampaio Tavares-
Autor(es): dc.creatorFormiga, Fabio Rocha-
Data de aceite: dc.date.accessioned2026-02-09T11:19:40Z-
Data de disponibilização: dc.date.available2026-02-09T11:19:40Z-
Data de envio: dc.date.issued2020-09-09-
Data de envio: dc.date.issued2023-06-27-
Data de envio: dc.date.issued2020-09-09-
Data de envio: dc.date.issued2023-06-27-
Data de envio: dc.date.issued2020-10-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br//handle/1/57690-
Fonte completa do material: dc.identifierhttps://doi.org/10.1016/j.actatropica.2020.105595-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1138531-
Descrição: dc.description17-N-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) is an inhibitor of heat shock protein 90 (Hsp90), which has been studied in the treatment of cancer such as leukemia or solid tumors. Alternatively, 17-AAG may represent a promising therapeutic agent against leishmaniasis. However, the delivery of 17-AAG is difficult due to its poor aqueous solubility. For exploring the therapeutic value of 17-AAG, we developed solid lipid nanoparticles (SLN) by double emulsion method. SLN exhibited ~100 nm, PDI < 0.2 and zeta potential ~20 mV. In addition, SLN were morphologically spherical with negligible aggregation. The entrapment efficiency of 17-AAG into the lipid matrix reached at nearly 80%. In a separate set of experiments, fluorescent SLN (FITC-labeled) showed a remarkable macrophage uptake, peaking within 2 h of incubation by confocal microscopy. Regarding the drug internalization as critical step for elimination of intracellular Leishmania, this finding demonstrates an important feature of the developed SLN. Collectively, these data indicate the feasibility of developing SLN as potential delivery systems for 17-AAG in leishmaniasis chemotherapy.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceActa Tropica-
Palavras-chave: dc.subject17-n-allylamino-17-demethoxygeldanamycin (17-aag)-
Palavras-chave: dc.subjectSolid lipid nanoparticles (sln)-
Palavras-chave: dc.subjectIn vitro uptake-
Palavras-chave: dc.subjectMacrophages-
Palavras-chave: dc.subjectLeishmaniasis-
Palavras-chave: dc.subjectTanespimicina-
Palavras-chave: dc.subjectNanopartículas lipídicas sólidas-
Palavras-chave: dc.subjectMacrófagos-
Palavras-chave: dc.subjectLeishmaniose-
Título: dc.titleSolid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against leishmania infections: Preparation, characterization and macrophage uptake-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.